Stock IXHL INCANNEX HEALTHCARE INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Incannex Healthcare Inc.

Equities

IXHL

US45333F1093

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-28 EDT 		5-day change 1st Jan Change
2.86 USD +2.88% Intraday chart for Incannex Healthcare Inc. +6.72% -38.36%
05-07 Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder CI
03-05 Incannex Healthcare Inc. Announces CFO Changes CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
AQ
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder
CI
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)
NE
Incannex Healthcare Inc. Quarterly Update, Q1 2024
AQ
Incannex Healthcare Inc. Announces CFO Changes
CI
Incannex Healthcare Inc. Announces Executive Changes
CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
AQ
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA
MT
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
AQ
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N
CI
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Clarion Clinics Open for Psychedelic-Assisted Treatments
AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
CI
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
AQ
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder
CI
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial
MT
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
AQ
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IXHL Stock
  4. News Incannex Healthcare Inc.